JIP
MRKR icon

Jaffetilchin Investment Partners’s Marker Therapeutics MRKR Stock Holding History

Jaffetilchin Investment Partners’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,550
Closed -$71K – 392
2021
Q2 		$71K Sell
2,550
-450
-15% -$11.8K ﹤0.01% 366
2021
Q1 		$67K Buy
+3,000
New +$68.6K 0.01% 358

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Jaffetilchin Investment Partners's MRKR Position: Q3 2021 in Review

Jaffetilchin Investment Partners sold out of Marker Therapeutics (MRKR) in Q3 2021, closing a stake of 2,550 shares — an estimated $71K sold.

Jaffetilchin Investment Partners first reported a position in MRKR in Q1 2021 and held it in 2 quarters. The position peaked at $71K in Q2 2021. 63 funds tracked by Wall St. Rank hold MRKR as of Q3 2021.

  • Jaffetilchin Investment Partners reported no remaining Marker Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 2,550 Marker Therapeutics shares in Q3 2021, an estimated $71K.
  • Jaffetilchin Investment Partners first reported a position in Marker Therapeutics in Q1 2021 and held it in 2 quarters.
  • Jaffetilchin Investment Partners's Marker Therapeutics position peaked at $71K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2021.

Based on Jaffetilchin Investment Partners's 13F filing for Q3 2021, filed 25 Oct 2021.